Search results - Portal of Medical Data Models (MDM-Portal)

Filter search results

Keywords

Psoriasis ×

Clinical Trial ×

Show more Keywords

Table of contents

Select data models

Selected data models

You must log in to select data models for download or further analysis.

29 Search results.

Screening Visit 1 Psoriasis NCT02695940

- 9/27/21 - 1 form, 10 itemgroups, 62 items, 1 language

Itemgroups: Administrative data,Eligibility criteria,Demography,Medical History,Treated body regions,Vital signs,ECG,Blood sample,Urine sample,miscellaneous

NCT02695940 A Phase 2a, Proof of Concept Trial, Testing Twice Daily Application of LEO 124249 Ointment 30 mg/g in the Treatment of Mild to Moderate Inverse Psoriasis. Quelle: Prof. Dr. Dr. h.c. Thomas Luger University Hospital of Muenster Department of Dermatology

Eligibility NCT00408187 Psoriasis - Eligibility

- 9/20/21 - 1 form, 2 itemgroups, 30 items, 2 languages

Itemgroups: Inclusion Criteria,Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00408187

Eligibility NCT00606450 Psoriasis - Eligibility

- 9/20/21 - 1 form, 2 itemgroups, 24 items, 2 languages

Itemgroups: Inclusion Criteria,Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00606450

Eligibility NCT01194219 Plaque Psoriasis - Eligibility

- 9/20/21 - 1 form, 2 itemgroups, 29 items, 2 languages

Itemgroups: Inclusion Criteria,Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT01194219

Eligibility NCT00329303 Psoriasis - Eligibility

- 9/17/21 - 1 form, 2 itemgroups, 10 items, 2 languages

Itemgroups: Inclusion Criteria,Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00329303

Eligibility NCT00245765 Chronic Plaque Psoriasis - Eligibility

- 9/17/21 - 1 form, 2 itemgroups, 12 items, 2 languages

Itemgroups: Inclusion Criteria,Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00245765

Eligibility NCT00852670 Plaque Psoriasis - Eligibility

- 9/17/21 - 1 form, 2 itemgroups, 7 items, 2 languages

Itemgroups: Inclusion Criteria,Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00852670

Eligibility NCT00574249 Chronic Plaque Psoriasis - Eligibility

- 9/17/21 - 1 form, 2 itemgroups, 11 items, 2 languages

Itemgroups: Inclusion Criteria,Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00574249

Eligibility Psoriatic Arthritis in Psoriasis NCT01316224

- 6/15/21 - 1 form, 2 itemgroups, 11 items, 1 language

Itemgroups: Inclusion Criteria,Exclusion Criteria

Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment; ODM derived from: https://clinicaltrials.gov/show/NCT01316224

PASI Psoriasis MIPSO EudraCT 2014-003022-40

- 6/11/18 - 1 form, 2 itemgroups, 33 items, 1 language

Itemgroups: Use of the form,Psoriasis Area and Severity Index

MIPSO Vergleichende Untersuchung der bakteriellen Mikrobiota in der Haut sowie dem Darm von Psoriasis-Patienten vor und nach systemischer Behandlung mit Adalimumab bzw. Ustekinumab oder Ciclosporin (EudraCT 2014-003022-40) Principal Investigator: Prof. Dr. Dr. h.c. Thomas A. Luger PASI: Fredriksson T, Pettersson U: Severe psoria - sis – Oral therapy with a new retinoid. Dermatologica 178; 157: 238–244.

Visit 6 Psoriasis NCT02695940

- 1/22/18 - 1 form, 8 itemgroups, 50 items, 1 language

Itemgroups: Administrative data,Medical History and physical exam,Vital signs,ECG,Blood sample,Urine sample,Picture,Signature

NCT02695940 A Phase 2a, Proof of Concept Trial, Testing Twice Daily Application of LEO 124249 Ointment 30 mg/g in the Treatment of Mild to Moderate Inverse Psoriasis. Quelle: Prof. Dr. Dr. h.c. Thomas Luger University Hospital of Muenster Department of Dermatology

Visit 7 Psoriasis NCT02695940

- 1/22/18 - 1 form, 3 itemgroups, 7 items, 1 language

Itemgroups: Administrative data,Medical History and Physical Examination,signature

NCT02695940 A Phase 2a, Proof of Concept Trial, Testing Twice Daily Application of LEO 124249 Ointment 30 mg/g in the Treatment of Mild to Moderate Inverse Psoriasis. Quelle: Prof. Dr. Dr. h.c. Thomas Luger University Hospital of Muenster Department of Dermatology

Please use this form for feedback, questions and suggestions for improvements.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.